Singapore's Scigen to expand local R&D

The Industry, Trade and Labor Ministry announced on Wednesday that the pharmaceutical company Scigen, headquartered in Singapore, intends over the next year to expand its research and development projects in Israel.

By MATTHEW KRIEGER
June 7, 2007 06:59

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Industry, Trade and Labor Ministry announced on Wednesday that the pharmaceutical company Scigen, headquartered in Singapore, intends over the next year to expand its research and development projects in Israel. Scigen manufactures the Hepatitis B vaccine, the main component for which was developed in Israel by Biotechnology General, said Rachel Roei, director of the Ministry's investment promotion center. Scigen, founded in 1988, is one of Singapore's leading bio-pharmaceutical companies and is traded on the Australian Stock Exchange.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS